Chugai's Value Creation & Sustainability - Chugai reorganized its value creation process in 2024, using materiality as axes, aiming to realize advanced and sustainable patient-centric healthcare[9] - The company focuses on creating innovative drugs and services, providing individualized solutions, ensuring quality, and co-creating a healthcare ecosystem[12] - Chugai is implementing materiality by aligning business activities with its materiality story, reflected in management strategies and division activities[14, 16, 20] - A project using the antibody drug discovery support technology MALEXA has advanced to clinical development stage[22, 23] - The company is constructing a disease database for blood coagulation disorders in cooperation with patient associations and academia[29, 35] - Chugai achieved 100% renewable energy ratio in purchased electricity[39] Mid-Size Molecule Drug Platform - Chugai is establishing a pharmaceutical technology platform for mid-size molecule drugs to provide new treatment options[6, 52] - The company is developing a new liquid-phase synthesis method to improve the efficiency of producing mid-size molecules[65] - Through joint research, the cost of certain non-natural amino acids was reduced to less than one third[77] - A 55.5 billion yen investment was made in Fujieda in 2024, 128.8 billion yen in Yokohama in 2022, and 4.5 billion yen in Ukima in 2020[90] Governance and Shareholder Value - Chugai emphasizes dialogue with investors to enhance governance and increase shareholder value[120] - Non-executive directors play a key role in monitoring and advising on management from a global perspective[129] - The company's average annual Total Shareholder Return (TSR) for the past 10 years is 23.5%, compared to 9.5% for TOPIX and 7.8% for TOPIX-17 Pharmaceutical Index[150]

Immutep Overview - Immutep has approximately A$109.85 million in cash and cash equivalents, providing a runway to the end of CY2026[14] - Immutep is developing four clinical-stage assets, including eftilagimod alfa (efti) and IMP761, designed to empower the immune system to fight cancer and autoimmune diseases[14] TACTI-004 (KEYNOTE-F91) Phase III Trial - The NSCLC drug market is expected to reach US$48 billion in sales in 2031[14,24] - The TACTI-004 Phase III trial has activated over 100 clinical sites across 24 countries and enrolled over 170 patients as of October 2025[25,30] - MSD is supplying KEYTRUDA for the TACTI-004 trial, with a typical ICI supply value of approximately US$100 million[30,32] Efficacy and Safety - In the INSIGHT-003 trial, a 62.7% objective response rate and a 90.2% disease control rate were observed across all PD-L1 expression levels in first-line NSCLC patients[52] - The EFTISARC-NEO trial in soft tissue sarcoma met its primary endpoint, demonstrating a median 51.5% tumor hyalinization/fibrosis rate (p<0.001) with neoadjuvant efti + KEYTRUDA + radiotherapy[52,70] Financials - Immutep's total revenue and other income were A$10.3 million in FY25, compared to A$7.8 million in FY24[79,80] - Research and development and intellectual property expenses increased to A$61.4 million in FY25[79,80] - The company reported a net loss of A$61.4 million in FY25[79] Intellectual Property - In FY24, seven patents were granted for efti, including six patents for efti in combination with a PD-1 pathway inhibitor[84] - Seven patents were granted for IMP761 in FY24[84] Anti-PD-(L)1 Therapies Sales - KEYTRUDA sales were approximately $29.5 billion in 2024[50,51] - OPDIVO sales were approximately $9.3 billion in 2024[50,51]

Daikin's Growth in the North American Data Center Cooling Market November 27, 2025 Today's Agenda 2 • Data Center Market in North America and Our Strategic Goals • Evolving Cooling Needs and Our Initiatives • Future Outlook North American Data Center Cooling Market Trends and Our Perspective 0 0.5 1 1.5 2 2.5 3 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 North American Data Center Cooling market Trend (company estimate) (T JPY) Approx. ¥1.1T Approx. ¥2.7T 3 Our Business Plan and Strategy 2023 2025 203 ...

Company Overview - NOVONIX is positioned as a leading domestic supplier of battery-grade synthetic graphite in North America[32] - The company is commercializing patented cathode synthesis technology to minimize environmental impact while producing high-performance materials[32] - NOVONIX offers industry-leading Ultra-High Precision Coulometry cell testing equipment and R&D services[32] Market and Competition - China dominates graphite production and export, accounting for approximately 95% of global supply[42] - China has imposed and tightened export controls on certain graphite items[42] - The US faces a structural market deficit for traditional Active Anode Material (AAM), forecasted to exceed 500kt/year over the next decade[51] Industrialization and Production - NOVONIX's Riverside facility is scaling to 20k tpa aligned with customer demand[63] - The company was awarded a $100 million DoE MESC grant and allocated up to $103 million in 48C investment tax credit for the Riverside facility[63] - NOVONIX Enterprise South is expected to have a full production capacity of 31.5k tpa, bringing the company's total production capacity to over 50k tpa[68] Commercial Traction - NOVONIX has a 4-year commitment totaling 10,000 tonnes with Panasonic and a 5-year commitment for a minimum of 32,000 tonnes with PowerCo starting in 2027[72] - The company is currently sampling to 15 current and potential customers[72] - NOVONIX delivered its first mass production, commercial-grade sample of synthetic graphite for industrial applications[83]

Argentine Economy - Real Gross Domestic Product is projected to increase by 3.6% in 2025 and 3.9% in 2026[5] - The Non-Financial Public Sector's Primary Fiscal Balance is projected to be 0.3% of GDP in both 2025 and 2026[14] - The Argentine Central Bank financing is projected to be 0.6% of GDP in 2025[16] - The current account is projected to be 0.3% of GDP in 2025[25] - Exports are projected to reach $81.5 billion in 2025 and $82.9 billion in 2026[26] Argentine Financial System - Financial Depth: Deposits are 18% of GDP and Loans are 10% of GDP in Argentina[44] - Private Sector Deposits increased 135.2% YoY and Private Sector Credit increased 135% YoY as of November 2025[49, 51] - As of August 31, 2025, Private Sector Banks hold 30.8% of the market share of private-sector deposits[62] - As of September 2025, the banking system's ROE is -0.1% and ROA is 0.0%[66, 67] Grupo Financiero Galicia (GFG) - GFG's ROE for 3Q25 was (4.7)% and ROA was (0.8)%[83] - Banco Galicia's ROE for 3Q25 was (7.3)% and ROA was (1.3)%[92] - Naranja X's ROE for 3Q25 was (2.5)% and ROA was (0.4)%[159]

Financial Performance - FY2025 - Deere & Company's FY2025 net sales and revenues reached $51716 million, a 13% increase compared to $45684 million in FY2024[7] - Net sales for equipment operations in FY2025 were $44759 million, up 15% from $38917 million in FY2024[7] - Net income attributable to Deere & Company for FY2025 was $7100 million, a 29% increase compared to $5027 million in FY2024[7] - Diluted earnings per share (EPS) for FY2025 were $2552, a 28% increase compared to $1850 in FY2024[7] Financial Performance - 4Q2025 - Net sales and revenues for 4Q2025 were $12394 million, a 11% increase compared to $11143 million in 4Q2024[9] - Net sales for equipment operations in 4Q2025 were $10579 million, up 14% from $9275 million in 4Q2024[9] - Net income attributable to Deere & Company for 4Q2025 was $1065 million, a 14% decrease compared to $1245 million in 4Q2024[9] - Diluted earnings per share (EPS) for 4Q2025 were $393, a 14% decrease compared to $455 in 4Q2024[9] Segment Performance - 4Q2025 - Production & Precision Ag net sales in 4Q2025 were $4740 million, a 10% increase compared to $4305 million in 4Q2024[11] - Small Ag & Turf net sales in 4Q2025 were $2457 million, a 7% increase compared to $2306 million in 4Q2024[13] - Construction & Forestry net sales in 4Q2025 were $3382 million, a 27% increase compared to $2664 million in 4Q2024[24] Financial Outlook - FY2026 - Deere & Company forecasts a net income attributable to the company of $40-475 billion for FY2026[35] - The company anticipates an effective tax rate of 25-27% for FY2026[35] - Net operating cash flow for FY2026 is projected to be $40-50 billion[36] - Capital expenditures are expected to be approximately $14 billion[37]

Financial Performance - Total revenue for FY25 was $562 million[3], impacted by a cyber incident that reduced revenue by approximately $12 million[4] - Digital revenue accounted for 53% of total revenue in FY25[3] - Adjusted EBITDA for FY25 was $45 million[3], also impacted by the cyber incident which reduced Adjusted EBITDA by approximately $8 million[4] - Q4 2025 total operating revenue was $139 million, a 12% year-over-year decrease, or a 5% decrease on a same-store basis[6] - Q4 2025 total digital revenue was $74 million, a 3% year-over-year decrease[6] - Q4 2025 total print revenue was $65 million, an 8% decrease[6] - Q4 2025 Adjusted EBITDA was $15 million, a 14% increase on a comparable basis[9] - The company has reduced gross debt by $121 million since refinancing in March 2020[40] Digital Growth - Digital subscription revenue grew 16%[3, 11, 22] - The company aims to achieve over $450 million in digital revenue by 2030 through its Three Pillar Digital Growth Strategy[13] - The company expects to surpass 12 million subscribers in 2030[43, 51] - The company is targeting $250 million of digital advertising[46, 51]

Market Overview - The global dry bulk fleet is aging, with 25% being over 15 years old[8] - Japan accounts for 42% of the global dry bulk fleet[8] - The dry bulk orderbook represents 107% of the existing fleet[8] - Approximately 15% of the dry bulk orderbook will be able to use alternative fuels upon delivery[8] - Global GDP is projected to grow by 31% in 2026 and 32% in 2027[17] - Global inflation is expected to be 37% in 2026 and 34% in 2027[17] - Dry bulk demand is forecasted to increase by 2% in 2026[17] - Supply is expected to increase by 28% in 2026 and 27% in 2027[21] Company Financials - The company declared a quarterly dividend of $005 per share, resulting in a 41% dividend yield[26] - Net revenues for the quarter were $731 million[26]

Financial Performance - Net Income decreased by 40% YoY and 46% QoQ[3] - Net Interest Income decreased by 33.6% YoY and 25.3% QoQ[8] - Financial Margin increased by 286.3% YoY and 37.1% QoQ[8] - Efficiency Ratio was 57.6% in 3Q25[8] Loan Portfolio & Asset Quality - Private Loans increased by 13.4% YoY[18] - Private Loans increased by 6% QoQ[18] Digital Transformation - Digital & Mobile Active Clients increased by 7% and 6% YoY respectively[37, 38] - Total liquid assets/ total deposits increased by 10%[28] Deposits & Capital - Private Deposits Market Share reached 10.09%[28] - Capital ratio declined[29] - Public sector exposure increased[31]

Business Performance - Loan book grew by 8% QoQ, outperforming the industry growth of 7.6%[8] - Total deposits increased by 15% QoQ and 40% YoY[8] - US$ deposits reached record levels, up 31% QoQ and 56% YoY[8] - Net fee income increased by 7% QoQ and 9% YTD[8] Profitability and Asset Quality - The company experienced a net loss of 50 billion in 3Q25 due to increased Cost of Risk (COR)[8] - Net Interest Margin (NIM) declined to 11%[8] - NPL ratio increased to 3.9%[8] - Net COR was 6.4% in 3Q25 and 5.2% YTD[8] Strategic Initiatives and Capital - CET1 ratio stood at 13.2% as of September 2025, increasing to 14.5% by October 2025[8, 18] - The company continued to evolve its SuperApp[8] - Cost reduction of 2% QoQ and 12% YTD was achieved[8] Macroeconomic Context - The Central Bank Market Expectations Survey as of October 2025 projected inflation of 30%, an Fx eop at 1,532, and GDP growth of 3.9% in 2025[15, 19]